Hyderabad-based drug maker Aurobindo Pharmaceuticals said in a filing with the Bombay Stock Exchange that has received temporary approval for Tenofovir Disoproxil Fumarate tablets, 300 mg from the US Food and Drug Administration.
Tenofovir Disoproxil Fumarate tablets, 300 mg is the generic equivalent of Gilead Science Inc's Viread Tablets 300mg and falls under the anti-retroviral segment.
It is indicated in combination with other anti-retroviral for the treatment of HIV-1 infection in adults. Aurobindo has obtained a license from Gilead to market Tenofovir products in 95 Developing and least developed countries.
Aurobindo now has a total of 91 abbreviated new drug application (ANDA) approvals from USFDA. Sixty-six of these are final and 25 are tentative, the filing said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app